IL13RA2 and neoplasm: An ongoing clinical trial with intraventricular administration of IL-13Rα2 CAR T cells for recurrent or refractory malignant glioma revealed significant tumor volume reduction in one patient, followed by complete response for more than 7.5 months [80].